Current Edition

The Need to Streamline Adverse Event Reporting for Clinical Trials

Given limitations in study size, duration and increasingly earlier approvals, pharmaceutical companies must garner as much relevant, accurate and timely data as possible to understand the true efficacy and safety profile of products during the development process. Dr Andrew Rut, MyMeds&Me, explores how consistent, high quality standardised and complete data is a foundation of successful clinical trials and drug development.